<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02731118</url>
  </required_header>
  <id_info>
    <org_study_id>Sal/2016</org_study_id>
    <nct_id>NCT02731118</nct_id>
  </id_info>
  <brief_title>Antisecretory Factor (AF) Effects on Intraocular-pressure</brief_title>
  <official_title>Antisecretory Factor (AF) Effects on Intraocular-pressure: a Placebo-controlled Randomised Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Erik Eye Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Erik Eye Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is a complex and chronic eye disease which damages the optic nerve. One of the main
      risk factors for the progression of glaucoma is IOP.

      The aim of the study is to examine if Salovum, an anti-secretory factor (AF), can reduce the
      level of the intraocular pressure (IOP) in the eye of patients affected by glaucoma.

      Anti-secretory factor (AF) is an endogenous protein which controls the transport of water and
      ions across the cell membrane. AF plays an important part in the immune system and has an
      anti-secretory and anti-inflammatory effect.

      The investigators' hypothesis is that Salovum can restore a normal salt-water balance in the
      eye, which in turn would lower the IOP. This would eliminate or reduce the risk of subsequent
      visual impairments/neurological damage.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the study is to examine if Salovum, an anti-secretory factor (AF), can reduce the
      level of the intraocular pressure (IOP) in the eye of patients affected by glaucoma.

      Glaucoma is a complex and chronic eye disease which damages the optic nerve. Beginning at the
      periphery of the vision field, it often progresses very slowly, which means that the patients
      consult a doctor only when damages have become very large. Glaucoma requires a lifelong
      medical treatment. Regardless of the medical treatment, damaged nerve fibers will never
      regenerate. An early onset of the medical treatment is crucial to avoid the progression of
      the disease which, if not treated, would also affect the central vision, resulting in
      patients with severe handicap.

      One of the main risk factors for glaucoma is elevated IOP and treatment is aimed to reduce
      its progression by IOP lowering. About 10-15 % of glaucoma patients following a medically
      correct treatment respond poorly or not at all to the medicines, leading to a progressive
      loss of the visual field and an increasingly defective eyesight.

      Anti-secretory factor (AF) is an endogenous protein which has been characterized in vivo and
      in vitro. AF is a part of the proteasome and controls the transport of water and ions across
      the cell membrane. AF plays an important part in the immune system and has an anti-secretory
      and anti - inflammatory effect in vivo along with complementary substances, primarily c3C.
      Researchers have chemically characterized and cloned AF's cDNA and shown that the active part
      (anti-secretory and anti-inflammatory) is located in the amino terminal portion of the
      protein. The exact mechanisms behind AF's regulatory effect on the secretory / inflammatory
      progress, however, is largely unknown, but AF is probably involved in the liquid transport
      mechanisms in the cell pathway.

      AF has been detected in most of the body tissues, plasma, breast milk, bile and faeces. In
      healthy individual, AF occurs principally in an inactive form, but AF can be activated by a
      disease, e.g. the toxin-induced diarrhea. The transition from inactive to active AF
      contributes to the normalization of the intestinal secretion and diarrhea decreases or
      ceases. In human beings, AF therapy has reduced disease symptoms such as ulcerative colitis,
      Crohn's disease, Meniere's disease, mastitis (inflammation of the mammary gland ) and during
      diarrhea conditions of different genesis. AF treatment has been particularly successful in
      the treatment of children's diarrhea and is routinely used in Pakistan. No side effects of
      therapy have so far been reported. Experiences in rats have also shown that AF is effective
      in lowering the pressure in the tissue tumors (breast cancer), lowering the elevated
      intracranial pressure that arises in connection with virus-induced inflammation of the brain
      (herpesvirus type 1), reducing the pressure caused by mechanical brain damage that mimic
      stroke (frost damage).

      By giving egg-producing hens special feed, hens' own production of AF is stimulated. The high
      content of AF is specifically reflected in the egg yolk with a level about 10,000 times
      higher than in normal eggs. The AF enriched egg yolk is subjected to spray-drying and sealed
      in bags containing 4 gr each. This product is named Salovum and has been registered as a food
      for specific medical purposes through the regulatory authorities in the EU. However, Salovum
      cannot be used in patients with diagnosed or suspected with egg allergy.

      The investigators' hypothesis is that Salovum can restore a normal salt-water balance in the
      eye, which in turn would lower the IOP. This would eliminate or reduce the risk of subsequent
      visual impairments/neurological damage. It is in this context important to point out that the
      intake of Salovum counts as food and does not in any way interfere with the conventional
      medical management of glaucoma.

      Fifty glaucoma patients who despite adequate medication need additional IOP lowering will be
      recruited. Participants will be randomly divided into 2 groups with 25 patients each and will
      be treated according to the following:

        -  one group begins with Salovum during 2 weeks and then take a placebo for another 2 weeks

        -  one group begins with placebo for 2 weeks and then takes Salovum 2 weeks.

      Dosage: Salovum is dissolved in juice or water and may give rise to a certain satiety. Each
      bag contains 4 gr of dried egg yolk. The first 2 days, the patients will take one bag of
      Salovum or placebo 6 times a day , then a bag 5 times daily for 3 days and finally a bag 4
      times daily for 9 days.

      The eye which has the highest IOP will be selected. If both eyes have the same IOP, the right
      eye will be chosen. IOP will be measured according to Goldmann applanation tonometry five
      times during the study period. IOP will be measured three times per session and all three
      measurements will be used for statistical analysis. IOP will also be measured with a
      self-tonometer by the patients themselves 5 times daily.

      Patients will get more detailed information about handling the self-tonometer from study
      staff. All results will be stored at St Erik Eye Hospital in a computer system with limited
      access.

      During the study, patients will continue to take their glaucoma treatment as usual. Except
      for drinking Salovum and measuring their IOP, no new routine will encounter.

      As the study will compare placebo (egg yolk with a low level of AF) with active treatment
      (Salovum with a high dose of AF) within a sick patient population, no healthy subjects will
      be included in the study.

      If an IOP lowering effect is achieved with Salovum, the investigators will discuss with the
      patient how treatment should be continued. If no effect is obtained, patients will continue
      with their usual medical treatment only.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intraocular pressure (IOP)</measure>
    <time_frame>2 weeks</time_frame>
    <description>IOP lowering effect of treatment or placebo over 14 days</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Placebo and Salovum</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 times 4 gr placebo/Salovum day 1-2, 5 times 4 gr placebo/Salovum day 3-5, 4 times 4 gr placebo/Salovum day 6-14</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salovum and placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 times 4 gr Salovum/placebo day 1-2, 5 times 4 gr Salovum/placebo day 3-5, 4 times 4 gr Salovum/placebo day 6-14</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Salovum</intervention_name>
    <description>AF-enriched egg yolk</description>
    <arm_group_label>Placebo and Salovum</arm_group_label>
    <arm_group_label>Salovum and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>egg yolk</description>
    <arm_group_label>Placebo and Salovum</arm_group_label>
    <arm_group_label>Salovum and placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  open angle glaucoma, ocular hypertension

        Exclusion Criteria:

          -  other types of glaucoma, other types of ocular comorbidity, previous intra-ocular
             surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enping Chen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Erik Eye Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Enping Chen, MD PhD</last_name>
    <phone>004686720000</phone>
    <email>enping.chen@sll.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Laurence Qu√©rat, M Sc</last_name>
    <phone>004686723240</phone>
    <email>laurence.querat@sll.se</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St Erik Eye Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>112 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enping Chen, MD PhD</last_name>
      <phone>004686720000</phone>
      <email>enping.chen@sll.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2016</study_first_submitted>
  <study_first_submitted_qc>April 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2016</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>St. Erik Eye Hospital</investigator_affiliation>
    <investigator_full_name>Enping Chen</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>glaucoma</keyword>
  <keyword>intraocular pressure lowering treatment</keyword>
  <keyword>antisectory factor (AF)</keyword>
  <keyword>Salovum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antisecretory factor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

